Quest Partners LLC Takes $313,000 Position in Eli Lilly and Company (NYSE:LLY)

Quest Partners LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, Holdings Channel reports. The fund purchased 537 shares of the company’s stock, valued at approximately $313,000.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $36,000. St. Johns Investment Management Company LLC grew its stake in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after buying an additional 37 shares during the last quarter. O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 31 shares during the last quarter. Finally, Bay Harbor Wealth Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $44,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on LLY. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Barclays raised their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $769.53.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $807.43 on Friday. The firm has a market cap of $767.39 billion, a PE ratio of 118.91, a price-to-earnings-growth ratio of 1.76 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $820.60. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company’s 50-day moving average price is $765.47 and its two-hundred day moving average price is $692.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.62 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.